logo
Northwell Health Commits $1.3M to Fund Employee

Northwell Health Commits $1.3M to Fund Employee

Business Wire08-05-2025

NEW HYDE PARK, N.Y.--(BUSINESS WIRE)--Three employee-led projects at Northwell Health, New York's largest health system, have been awarded a total of $1.3 million in funding as part of its 2025 Innovation Challenge. The funding will support the development of innovative approaches to care delivery and scientific advancement aiming to transform the future of health care. The announcement was made during the health system's Made for Big Ideas™ Showcase on May 1.
Lead investigators of the three winning projects included:
Phillip Connell, MD, Northwell Obstetrics and Gynecology gynecologic surgery fellow, for his work on a new technology platform that connects operating room monitors, a wireless camera and extended reality (XR) glasses for streaming of high quality, low latency video;
Eric Gantwerker, MD, pediatric otolaryngologist at Northwell Health's Cohen Children's Medical Center in New Hyde Park, for his work on an artificial intelligence (AI)-enabled detection program that can help diagnose pediatric sleep apnea based on sound recordings from home devices;
Matthew Barish, MD, vice-chair of the Imaging Service Line, CMIO, for his work on an all-in-one radiology platform for AI insights, clinician feedback and continuous diagnostic improvement.
'At Northwell, we're proud to cultivate a culture that empowers our team members — no matter what department you work in – to promote innovative and new ways of thinking to improve how we deliver care,' said Michael Dowling, Northwell president and CEO. 'These submissions showcase our team's most unique approaches for addressing major health care challenges.'
Hundreds of Northwell employees have submitted ideas to the competition since it launched in 2017. To date, the health system has awarded funding for 15 projects to help advance their projects and develop their inventions. After a rigorous screening process, six finalist teams are chosen to present their pitches in person to an esteemed panel of judges. This year's judges included:
Bunny Ellerin, digital health expert and entrepreneur
Jessica Federer, board member of Angelini Ventures
Sunny Kumar, MD, partner at Informed Ventures
Russ Richmond, MD, CEO and co-founder of Laudio
'At Northwell, our team members are our greatest asset, and we believe that the best ideas often come from the people closest to the work,' said Jason Naidich, MD, senior vice president and chief innovation officer at Northwell. 'This competition is a testament to Northwell's dedication to creating the future of healthcare and its unwavering support for the visionaries who lead the way.'
This year's winners include:
A new technology platform for the operating room
Presented by Dr. Connell and Johnny Zhang, specialist with the Biomedical Design Center for Learning Innovation, this invention combines a camera and XR glasses with existing operating room equipment, including monitors, cameras and lighting, to stream high-quality, low-latency video. The result is a portable, immersive experience offering real-time, AI-enhanced surgical assistance, including live remote expert consultations. This technology promises to transform laparoscopic surgery and expand access to minimally invasive procedures.
'This platform is going to start by increasing access to minimally invasive techniques locally and nationally,' said Dr. Connell. 'But it will also build into a platform that helps surgeons improve their efficacy and improve patient safety by not being inhibited by all the wires and bulky systems that currently surround the patient.'
Other team members include: Michael Nimaroff, MD, MBA, senior vice president and executive director of Northwell OB/GYN and chair OB/GYN at North Shore University Hospital and Long Island Jewish Medical Center; and Allison Neuwirth, project manager with the Biomedical Design of Center for Learning Innovation.
AI-enabled detection of pediatric sleep apnea
Presented by Dr. Gantwerker and Patrick Scheffler, MD, assistant professor otolaryngology at Northwell, this program helps collect data from home devices and applies it to AI-enabled analysis that can help diagnose pediatric obstructive sleep apnea, especially for families who cannot access sleep centers for studies.
'We're so excited for this funding so it can go directly into creating this application and make a big difference in pediatric sleep apnea care,' said Dr. Gantwerker. 'The goal is to expand access of sleep studies, especially for those who currently lack it, significantly improving patient outcomes.'
An all-in-one radiology platform
Presented by Dr. Barish and James Thannickal, this new program streamlines radiology workflows by seamlessly integrating and assessing various AI tools. This allows radiologists to efficiently review and incorporate AI-generated insights, leading to faster, more accurate diagnoses and improved patient care.
'Patient care can suffer when mistakes and different AI tools get in the way of clinical care,' said Thannickal. 'This program will not replace humans but help create a more streamlined process for radiologists for better patient outcomes.'
Other team members include David Hirschorn, MD, chief of informatics and imaging; and Daniel Nicosia, software engineer.
'Since 2017, the Innovation Challenge has consistently provided an exceptional platform for our Northwell colleagues to present their inventive solutions,' said Richard Mulry, president and CEO of Northwell Holdings. 'We are delighted to collaborate with them, furthering these advancements and broadening their influence on how care is provided and experienced not just within Northwell, but across the health care landscape.'
Northwell Holdings, the for-profit venture investment arm of Northwell, works with doctors, scientists, staff and entrepreneurs both in and out of the health system to advance the commercial potential for internal innovation and development of commercial joint ventures.
The last innovation challenge, held in 2023, awarded two transformative projects: iNav (AI-driven cancer patient navigation) and StrokeFighter (bioelectronic therapy for stroke) each received $500,000 to further their research and development. Other past projects funded have included research into the first non-invasive diagnostic test for endometriosis, a therapeutic drug candidate as a potential treatment for HPV infection, real-time actionable data related to ED utilization, and the allocation of clinical resources and infrared thermography for early detection of tissue pressure injury.
About Northwell Health
Northwell is the largest not-for-profit health system in the Northeast, serving residents of New York and Connecticut with 28 hospitals, more than 1,000 outpatient facilities, 22,000 nurses and over 20,000 physicians. Northwell cares for more than three million people annually in the New York metro area, including Long Island, the Hudson Valley, western Connecticut and beyond, thanks to philanthropic support from our communities. Northwell is New York State's largest private employer with over 104,000 employees – including members of Northwell Health Physician Partners and Nuvance Health Medical Practices – who are working to change health care for the better. Northwell is making breakthroughs in medicine at the Feinstein Institutes for Medical Research. Northwell is training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, X, Instagram and LinkedIn.
About the Feinstein Institutes:
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

"AI-First" Hype Gives Way to Reality: New Speechmatics Report Reveals What's Actually Working in AI
"AI-First" Hype Gives Way to Reality: New Speechmatics Report Reveals What's Actually Working in AI

Yahoo

time29 minutes ago

  • Yahoo

"AI-First" Hype Gives Way to Reality: New Speechmatics Report Reveals What's Actually Working in AI

CAMBRIDGE, UK, June 03, 2025--(BUSINESS WIRE)--After a wave of bold "AI-first" announcements from major tech players, many are now scaling back. As the AI gold rush slows, a new report from Speechmatics explores what's actually working — and where the real value lies. Titled The Voice AI Reality Check: Frontline Perspectives for Enterprise in 2025, the report zeroes in on one of the fastest-evolving areas of AI: Voice AI. Built on interviews with leaders across healthcare, compliance, media, public services, and research, it reveals a clear shift from flashy demos to embedded, operational AI — where tools assist humans, deliver measurable ROI, and quietly power core infrastructure. Report highlights include: Assistive over autonomous: The most effective deployments augment people rather than replace them. Assistive agents are driving real ROI. Multilingual as standard: Real-time code-switching is now a baseline requirement, not a bonus. Accuracy is make-or-break: With growing global concerns over AI hallucinations, precision is essential — especially in compliance-heavy environments. Voice as infrastructure: Quietly embedded tools are outperforming headline-grabbing features. Rather than betting on speculative demos, successful enterprises are treating Voice AI as critical infrastructure. It's being embedded into workflows that demand speed, accuracy, and trust — from noisy control rooms to multilingual contact centres. The report closes with future-looking predictions, outlining the rise of emotionally intelligent, adaptive, and natively multilingual voice systems — and offers guidance on what enterprises must prioritise next. Download the full report now. View source version on Contacts For interviews, images, quotes or media access, contact: Mieke Kyra, Content Lead

Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing
Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing

Yahoo

time33 minutes ago

  • Yahoo

Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing

LEIDEN, Netherlands, June 09, 2025--(BUSINESS WIRE)--Azafaros, a clinical-stage biotechnology company developing novel therapies for rare lysosomal storage disorders (LSDs), today announced that it will present at the 2025 BIO International Convention taking place in Boston, USA, from 16-19 June. The company's presentation is scheduled for Monday, June 16 at 16:45 ET in Room 153B. The presentation will highlight Azafaros' progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). This announcement follows Azafaros' recently completed and oversubscribed €132 million Series B financing round, which will support advancing nizubaglustat into pivotal clinical development. The company is on track to initiate two Phase 3 trials in GM1/GM2 gangliosidoses and NPC in 2025. Earlier this year, Azafaros reported positive topline results from its ongoing Phase 2 study evaluating nizubaglustat in patients with GM2 gangliosidosis and NPC. The current Ph2 extension study demonstrated a favorable safety profile after more than 12 months of treatment. In addition, preliminary improvements or stabilization in key clinical endpoints were observed in the majority of patients, underscoring promising efficacy trends for nizubaglustat. "We are excited to share our latest progress at BIO 2025, including the continued clinical development of nizubaglustat which holds strong potential as a meaningful treatment option for patients with devastating neurodegenerative lysosomal disorders," said Stefano Portolano, CEO at Azafaros. "With the support of our recent financing round and encouraging data from our ongoing trials, we can continue our rapid momentum to bring this product into pivotal clinical studies as we work to develop a potential new solution for this area where there is a significant unmet need." About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Paediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Jeito Capital, Forbion Growth, Seroba, Pictet Group and a syndicate of leading Dutch and Swiss existing investors including Forbion Ventures, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. View source version on Contacts For further information: Azafaros info@ Sign in to access your portfolio

FIA President Mohammed Ben Sulayem Looking Forward to Visiting ‘Iconic' Macau for the 2025 FIA Annual Conference
FIA President Mohammed Ben Sulayem Looking Forward to Visiting ‘Iconic' Macau for the 2025 FIA Annual Conference

Business Wire

time34 minutes ago

  • Business Wire

FIA President Mohammed Ben Sulayem Looking Forward to Visiting ‘Iconic' Macau for the 2025 FIA Annual Conference

MACAU--(BUSINESS WIRE)--The Fédération Internationale de l'Automobile (FIA), the global governing body for motorsport and the federation for mobility organisations worldwide, will shortly be in Macau for the 2025 FIA Extraordinary General Assembly and Annual Conference. Marking the first time this event has ever taken place in this diverse region, the conference will be hosted in partnership with the Automobile General Association Macao-China (AAMC) and Galaxy Entertainment Group and held at the Galaxy International Convention Centre. The event will welcome over 500 senior FIA delegates across mobility and motorsport from 149 countries, offering the opportunity to address key initiatives in road safety, sustainable mobility, regional sporting growth, and innovation in transport, with the FIA President Mohammed Ben Sulayem in attendance. Speaking ahead of his visit to Macau, FIA President Mohammed Ben Sulayem said: 'Global gatherings like this are vital to the health of our federation. Bringing our community together allows us an invaluable opportunity for engagement and participation, particularly within a pivotal election year. 'The Members of the FIA are at the heart of everything we do, and I am looking forward to being inspired by and connected to them over the next few days, strengthening the link between sport and mobility, expanding our reach, and continuing to impact the global stage. 'I am incredibly proud of the progress we have made together during my first term in office and look forward to continuing that partnership going forward. I am committed to the transformation of the FIA, so it can be an even more positive force for society. Globally, we remain committed to growing motorsport participation through grassroots initiatives and accessibility programmes such as the Affordable Cross Car and the Global Karting Plan. 'At the same time, we continue to empower all regions through our mobility capabilities, maintaining a central role in the automotive industry and leading the dialogue on the future of sustainable cities, safety, and transport.' Commenting on the location of this year's conference, Ben Sulayem said: 'Macau is iconic within the world of motorsport and a fitting location for the FIA to host one of the most important weeks of our calendar. I look forward to seeing much of what this unique destination has to offer.' The conference follows the FIA's recent announcement regarding the FIA's significant financial turnaround and strongest results in almost ten years. Reporting a profit of €4.7m, and an operating income of €182m for 2024, this puts the FIA back in the black following the inheritance of a €-24.0m deficit in 2021 from the previous administration. The conference will be attended by representatives from the 245 FIA Member Clubs. This structure forms the backbone of the federation's governance and operations, with each full Member Club holding voting rights across the FIA's elections and regulatory decisions. Clubs are grouped into two primary categories, with some serving in both roles: Mobility Clubs – provide mobility services and represent the interest of road users, with a focus on road safety, travel and tourism, consumer rights, and sustainable mobility National Sporting Authorities (ASNs) – govern and develop motorsport at a national level, are responsible for sporting events, issuing licenses, and engagement across regulations The Fédération Internationale de l'Automobile (FIA) is the governing body for world motor sport and the federation for mobility organisations globally. It is a non-profit organisation committed to driving innovation and championing safety, sustainability and equality across motor sport and mobility. Founded in 1904, with offices in Paris, London and Geneva, the FIA brings together 245 Member Organisations across five continents, representing millions of road users, motor sport professionals and volunteers. It develops and enforces regulations for motor sport, including seven FIA World Championships, to ensure worldwide competitions are safe and fair for all. The 2025 FIA Conference is hosted in association with Galaxy Entertainment Group and will be held at the International Convention Centre from 10-12 June. The Galaxy International Convention Centre is situated within the Galaxy Macau Integrated Resort which regularly plays host to world class sporting and conference events, and international exhibitions.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store